- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
X-rays are not the only way to peer inside the body without cutting into it: visible and especially infrared light can also be used to image human tissue. The effectiveness of optical imaging processes can be significantly improved with suitable dyes used as contrast agents. Now, as reported in the journal Angewandte Chemie International Edition, a team led by Wenbin Lin at the University of North Carolina has introduced a novel contrast agent that marks tumor cells in vitro. The dye is a phosphorescent ruthenium complex incorporated into nanoparticles of a metal-organic coordination polymer, which allows an extraordinarily high level of dye loading.
Fluorescent dyes accumulate in varying amounts in different types of tissue. Such contrast agents make it possible to use optical imaging to differentiate between healthy and malignant tissue. However, this method is limited by the fact that very high concentrations of dye are needed to produce sufficiently strong fluorescence. Organic dye molecules packed at high concentrations into nanocapsules tend to quench each other's fluorescence. Materials that fluoresce more strongly, such as quantum dots, are often not biocompatible.
Dr. Lin, who is the co-principal investigator of one of the 12 National Cancer Institute-funded Cancer Nanotechnology Platform Partnerships, and his colleagues have now developed an alternative - metal complexes connected to form lattice-like coordination polymers. Coordination polymers are metal-organic structures consisting of metal ions, which act as connecting points, linked by bridges made of organic molecules or coordination complexes. The scientists made such polymers with bridges consisting of a light-emitting complex of the metal ruthenium. Zirconium ions proved to be suitable connecting points. These tiny structures form spherical nanoparticles.
The ruthenium complexes do not fluoresce, but rather phosphoresce, which means that they emit light for a proportional length of time after irradiation with light. Because they are not placed inside a nano-transport container, but are a component of the nanoparticle, it is possible to attain a very high level of dye loading—in this instance over 50%. Quenching of the phosphorescence at high concentrations does not occur in such complexes.
In order to prevent the glowing particles from rapidly dissolving and to increase the biocompatibility, they were coated with thin layers of silicon dioxide and a layer of polyethylene glycol. The latter acts as an anchor point for anisamide, a molecule that specifically binds to receptors that are far more common on the surfaces of many types of tumor cell than on healthy cells.
In cell culture, it was possible to selectively mark a line of cancer cells with the phosphorescent nanoparticles. The researchers hope that it will be possible to develop contrast agents for the use of optical imaging for tumor detection based on these new metal-organic nanomaterials.
About The National Cancer Institute (NCI)
To help meet the goal of reducing the burden of cancer, the National Cancer Institute (NCI), part of the National Institutes of Health, is engaged in efforts to harness the power of nanotechnology to radically change the way we diagnose, treat and prevent cancer.
The NCI Alliance for Nanotechnology in Cancer is a comprehensive, systematized initiative encompassing the public and private sectors, designed to accelerate the application of the best capabilities of nanotechnology to cancer.
Currently, scientists are limited in their ability to turn promising molecular discoveries into benefits for cancer patients. Nanotechnology can provide the technical power and tools that will enable those developing new diagnostics, therapeutics, and preventives to keep pace with today’s explosion in knowledge.
For more information, please click here
National Cancer Institute
Office of Technology & Industrial Relations
ATTN: NCI Alliance for Nanotechnology in Cancer
Building 31, Room 10A49
31 Center Drive , MSC 2580
Bethesda , MD 20892-2580
Copyright © The National Cancer Institute (NCI)If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information